** Shares of Arovella Therapeutics rise as much as 15.7% to A$0.203, their biggest intraday pct gain since Oct 11, 2024
** The biotech firm says it secured A$20 mln ($12.39 mln) placement funding to wrap up inaugural clinical trial of lymphoma, leukemia drug ALA-101
** Placement is at an issue price of A$0.17 per share, representing a 2.9% discount to last trade
** Stock hits its highest level since mid-November 2024
** Over 4.5 mln shares change hands, 5.3x the 30-day avg
** Stock rose 47.8% in 2024
($1 = 1.6139 Australian dollars)
(Reporting by Kumar Tanishk in Bengaluru)
((Tanishk.Kumar@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。